1: Gonçalves BP, Tiono AB, Ouédraogo A, Guelbéogo WM, Bradley J, Nebie I, Siaka D, Lanke K, Eziefula AC, Diarra A, Pett H, Bougouma EC, Sirima SB, Drakeley C, Bousema T. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med. 2016 Mar 8;14(1):40. doi: 10.1186/s12916-016-0581-y. 2: Mssusa AK, Fimbo AM, Nkayamba AF, Irunde HF, Sillo HB, Shewiyo DH, Hill G, Minzi OM. Safety Profile of Artemether-Lumefantrine: A Cohort Event Monitoring Study in Public Health Facilities in Tanzania. Clin Drug Investig. 2016 Mar 7. [Epub ahead of print] doi: 10.1016/j.jcv.2016.02.006. Epub 2016 Feb 11. doi: 10.4269/ajtmh.15-0503. Epub 2016 Jan 25. doi: 10.1093/infdis/jiv551. Epub 2015 Nov 23. A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa. Clin Infect Dis. 2016 Feb 21. pii: ciw029. [Epub ahead of print] doi: 10.1038/tpj.2015.37. Epub 2015 May 12. doi: 10.1186/s12936-015-1080-x. 10: Parashar D, N P A, R S R M. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. Drug Deliv. 2016 Jan;23(1):123-9. doi: 10.3109/10717544.2014.905883. Epub 2014 Apr 30. doi: 10.1186/s12879-016-1345-1.